Optical Coherence Tomography (OCT) is a non-invasive diagnostic imaging technique that uses light to produce very high- resolution cross-sectional images of the tissue layers within the retina. These layers at the macula can then be studied and measured in microscopic detail. By comparing the structure and thickness of the layers measured by the OCT against a normal healthy retina, eye specialists can detect any Wet MD even at a very early stage. It is an important addition to thorough clinical examination and is now a standard diagnostic procedure in the diagnoses and ongoing management of Wet MD. Repeated tests are usually necessary to monitor disease activity.

Wet Macular Degeneration (MD) occurs when new abnormal blood vessels grow from the choroid into the retina. This process is called choroidal neo-vascularisation (CNV). Neo = new and vascularisation = vessel formation. There are a number treatments, both proven and experimental, available for people with Wet MD. The treatments target these new abnormal blood vessels that grow into the retina. The treatments are not curative and aim to keep the best vision for as long as possible.

In controlled trials Lucentis has been proven to be a safe and clinically effective treatment for Wet MD. With monthly injections Lucentis has shown to effectively control Wet MD and preserve vision in the majority of cases, and even improve it somewhat in a minority of cases.

Patients should discuss details of the injections with their eye specialist. Trials are looking at varying the frequency of injections and using it in combination with Photodynamic Therapy with Visudyne.

Lucentis is presently not funded by the government in New Zealand.